Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors

N/AWithdrawnNCT04019470

Capital Medical University

Overview

To investigate the effect of radiotherapy on peripheral blood immune cell composition and function in pediatric malignant brain tumor patients.

Study Type

OBSERVATIONAL

Conditions

Brain Tumor, Pediatric

Eligibility

Sex: ALLMin age: 3 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age from 3 to 18 * To be diagnosed with malignant brain tumors * To eligible for radiation therapy * Karnofsky performance status ≥ 70 * No prior radiation exposure * Informed consent signed for blood sample collection and used for research purpose Exclusion Criteria: * Patients had received radiotherapy previously. * Patients who had no histological diagnosis * Patients who do not wish to participate * Patients with infections

Locations (1)

Beijing Shijitan Hospital Cancer Center

Beijing, China

Outcomes

Primary Outcomes

The changes of peripheral blood immune cells

The flow cytometric analysis of lymphocyte subtypes populations would be performed

Time frame: 6 weeks (prior and post the radiation therapy )

Secondary Outcomes

Activation status of T cells

Activation status of peripheral IFN-γ-producing effector CD8+ T cells by Elispot.

Time frame: 6 weeks (prior and post the radiation therapy )

The changs of inflammatory cytokines and chemokines

Human inflammatory cytokines and chemokines will be analyzed by ELISA during radiation therapy. The cytokines and chemokines are IL-2, IL-10, IFN-γ, TNF-α

Time frame: 6 weeks (prior and post the radiation therapy )

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.